CD8A and melanoma: JQ1 combined with checkpoint blockade (anti-PD-1 or anti-CTLA-4) improved CD8+/Treg ratios and Th1 activation in melanoma and lung adenocarcinoma models (147), and similarly enhanced anti-tumor T cell responses in prostate cancer models (141).